Supernus Pharmaceuticals SUPN Accumulated Depreciation
Accumulated Depreciation at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's accumulated depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's accumulated depreciation?
- Supernus Pharmaceuticals (SUPN) reported accumulated depreciation of $18.75M in Q1 2026.
- How has Supernus Pharmaceuticals's accumulated depreciation changed year-over-year?
- Supernus Pharmaceuticals's accumulated depreciation increased by 1.7% year-over-year, from $18.44M to $18.75M.
- What is the long-term trend for Supernus Pharmaceuticals's accumulated depreciation?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's accumulated depreciation has grown at a 1.4% compound annual growth rate (CAGR), from $17.04M to $18.26M.
- What does accumulated depreciation mean?
- Total accumulated depreciation on property, plant, and equipment since acquisition — represents the consumed portion of asset useful lives.